Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	51,221
Balance at Dec. 31, 2020	$ 5	$ 191,348	$ 0	$ (151,408)	$ 39,945
Common shares issued for Trigr Therapeutics, Inc. acquisition (in shares)	10,265
Common shares issued for Trigr Therapeutics, Inc. acquisition	$ 1	50,299	0	0	50,300
Common shares issued in Public Offering, net of issuance costs of $8.5 million (in shares)	38,987
Common shares issued in Public Offering, net of issuance	$ 4	127,981	0	0	127,985
Share-based awards (in shares)	359
Share-based awards	$ 0	0	0	0	0
Stock-based compensation	0	4,029	0	0	4,029
Net loss	$ 0	0	0	(82,181)	$ (82,181)
Common stock issued upon exercise of options (in shares)					(0)
Unrealized loss on marketable securities					$ 0
Balance (in shares) at Dec. 31, 2021	100,832
Balance at Dec. 31, 2021	$ 10	373,657	0	(233,589)	140,078
Common shares issued in Public Offering, net of issuance costs of $8.5 million (in shares)	25,000
Common shares issued in Public Offering, net of issuance	$ 3	75,739	0	0	75,742
Share-based awards (in shares)	559
Share-based awards	$ 0	0	0	0	0
Stock-based compensation	0	5,330	0	0	5,330
Net loss	$ 0	0	0	(39,225)	$ (39,225)
Common stock issued upon exercise of options (in shares)	6				6
Common stock issued upon exercise of options	$ 0	15	0	0	$ 15
Cancelled shares (in shares)	(95)
Unrealized loss on marketable securities	$ 0	0	(302)	0	(302)
Balance (in shares) at Dec. 31, 2022	126,302
Balance at Dec. 31, 2022	$ 13	$ 454,741	$ (302)	$ (272,814)	$ 181,638